Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma

INTRODUCTION: Recent data from the COMPARZ study seem to suggest a non-inferiority of pazopanib confronted with sunitinib in PFS and OS. We previously reported how VEGF and VEGFR polymorphisms might have a predictive role in patients treated with first-line sunitinib. Aim of our study was to investi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Bianconi, Maristella, Faloppi, Luca, Loretelli, Cristian, Zizzi, Antonio, Giampieri, Riccardo, Bittoni, Alessandro, Andrikou, Kalliopi, Prete, Michela Del, Burattini, Luciano, Montironi, Rodolfo, Scartozzi, Mario, Cascinu, Stefano
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5122335/
https://ncbi.nlm.nih.gov/pubmed/27175586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9229
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars